Piet Wigerinck
Förmögenhet: 124 266 $ per 2026-05-31
Förmögenhet: 124 266 $ per 2026-05-31
Piet Wigerinck is the founder of Xinvento BV.
Current jobs include Independent Director at Ipsen SA since 2018, Director at Antwerp University Hospital, Independent Non-Executive Director at miDIAGNOSTICS NV, Independent Director at Atriva Therapeutics GmbH, and Director at Symeres BV.
Former jobs include Director at UZA Foundation, Chief Scientific Officer at Galapagos NV from 2012 to 2021, Vice President-Drug Discovery at Tibotec Virco Comm.
VA, and Vice President at Drug Discovery & Development Solutions Ltd. Education includes a doctorate from Katholieke Universiteit Leuven.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IPSEN SA 0 % | 2025-12-31 | 680 ( 0 % ) | 124 266 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| IPSEN | Direktör/Styrelseledamot | 2018-05-01 |
Antwerp University Hospital
Antwerp University Hospital Hospital/Nursing ManagementHealth Services Provides clinical, patient care, academic training and scientific research services | Direktör/Styrelseledamot | - |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services Develops a computer chip powered portable medical laboratory | Direktör/Styrelseledamot | - |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Direktör/Styrelseledamot | - |
Symeres BV
Symeres BV BiotechnologyHealth Technology Operates as a contract research organization for drug discovery and development activities | Direktör/Styrelseledamot | - |
| Företag | Position | Slut |
|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | Teknisk/Vetenskaplig/F&U Direktör | 2021-12-31 |
UZA Foundation | Direktör/Styrelseledamot | - |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Operates as a biotech company that develops therapies for congenital hyperinsulinism | Grundare | - |
Tibotec Virco Comm. VA
Tibotec Virco Comm. VA Pharmaceuticals: MajorHealth Technology Provides medicine | Företagsledare/Principal | - |
| ░░░░ ░░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 11 |
|---|---|
Ipsen SA
Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Galapagos NV
Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
Antwerp University Hospital
Antwerp University Hospital Hospital/Nursing ManagementHealth Services Provides clinical, patient care, academic training and scientific research services | Health Services |
Tibotec Virco Comm. VA
Tibotec Virco Comm. VA Pharmaceuticals: MajorHealth Technology Provides medicine | Health Technology |
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services Develops a computer chip powered portable medical laboratory | Commercial Services |
Drug Discovery & Development Solutions Ltd.
Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in drug discovery and development | Commercial Services |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Develops anti-tumour medicine | Health Technology |
Symeres BV
Symeres BV BiotechnologyHealth Technology Operates as a contract research organization for drug discovery and development activities | Health Technology |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Operates as a biotech company that develops therapies for congenital hyperinsulinism | Health Technology |
UZA Foundation |
Välj din utgåva
All finansiell information anpassad till den nationella nivån